The RING finger domain E3 ubiquitin ligases BRCA1 and the RNF20/RNF40 complex in global loss of the chromatin mark histone H2B monoubiquitination (H2Bub1) in cell line models and primary high-grade serous ovarian cancer

KA Dickson; AJ Cole; AJ Gill; A Clarkson; GB Gard; A Chou; CJ Kennedy; BR Henderson; S Fereday; N Traficante; K Alsop; DD Bowtell; A de Fazio; R Clifton-Bligh; DJ Marsh

Journal article

The RING finger domain E3 ubiquitin ligases BRCA1 and the RNF20/RNF40 complex in global loss of the chromatin mark histone H2B monoubiquitination (H2Bub1) in cell line models and primary high-grade serous ovarian cancer

KA Dickson, AJ Cole, AJ Gill, A Clarkson, GB Gard, A Chou, CJ Kennedy, BR Henderson, S Fereday, N Traficante, K Alsop, DD Bowtell, A de Fazio, R Clifton-Bligh, DJ Marsh

Human Molecular Genetics | OXFORD UNIV PRESS | Published : 2016

DOI: 10.1093/hmg/ddw362

Abstract

Enzymatic factors driving cancer-associated chromatin remodelling are of increasing interest as the role of the cancer epigenome in gene expression and DNA repair processes becomes elucidated. Monoubiquitination of histone H2B at lysine 120 (H2Bub1) is a central histone modification that functions in histone cross-talk, transcriptional elongation, DNA repair, maintaining centromeric chromatin and replication-dependent histone mRNA 3'-end processing, as well as being required for the differentiation of stem cells. The loss of global H2Bub1 is seen in a number of aggressive malignancies and has been linked to tumour progression and/or a poorer prognosis in some cancers. Here, we analyse a larg..

View full abstract

University of Melbourne Researchers

Julie Fereday Author

Nadia Traficante Author

Kathryn Alsop Author

Related Projects (5)

Australian Biospecimen Network-Oncology

Availability of ethically consented, clinically annotated human cancer tissue is a key determinant of the international competitiveness of A..

Molecular Epidemiology of Ovarian Research Institute

PUBLIC ABSTRACT A major obstacle to preventive strategies for ovarian cancer is the lack of recognized modifiable risk factors. Age, a pos..

Molecular Epidemiology of Ovarian Cancer: The Australian Ovarian Cancer Study National Clinical Follow-Up Core

Ovarian cancer is the seventh most common cancer in Australian women and fifth most common cause of cancer death, with approximately 1200 ne..

AUSTRALASIAN BIOSPECIMEN NETWORK-ONCOLOGY

AUSTRALIAN OVARIAN CANCER STUDY (AOCS): A MULTIDISCIPLINARY OVARIAN CANCER RESOURCE FOR THE GENOMICS ERA

Ovarian cancer is relatively uncommon and is histologically very diverse, making it difficult to analyse ovarian cancer at a molecular level..

Grants

Awarded by Medical Research and Materiel Command

Funding Acknowledgements

This work was supported by the Cancer Council NSW, Australia [RG13-10 to D.J.M., A.J.G. and G.B.G.]; Australian Research Council [FT100100489 to D.J.M]; National Health and Medical Research Council [APP1004799 to D.J.M], Australia Postgraduate Award and Sydney Medical School - Northern scholarship, Australia [to A.J.C.]. The Australian Ovarian Cancer Study was supported by the U.S. Army Medical Research and Materiel Command under DAMD17-01-1-0729, The Cancer Council Victoria, Queensland Cancer Fund, The Cancer Council New South Wales, The Cancer Council South Australia, The Cancer Foundation of Western Australia, The Cancer Council Tasmania and the National Health and Medical Research Council of Australia (NHMRC; ID400413, 10400281). The Gynecological Oncology Biobank at Westmead was funded by NHMRC Enabling Grants ID310670 & ID628903 and Cancer Institute NSW Grants 12/RIG/1-17 & 15/RIG/1-16. AdeF is funded by the University of Sydney Cancer Research Fund and the Cancer Institute NSW through the Sydney-West Translational Cancer Research Centre.